Apply to the InhibOx/NFCR
virtual screening service


The website of our FP6 consortium.


InhibOx works closely with
MolPort, a one-stop shop for
compound acquisition.

Paul completed his undergraduate degree at St Peter's College, Oxford and his biochemistry Ph.D. at the University of Manchester. Between 1985 and 1990, he worked as a scientist in the computational chemistry group at SmithKline Beecham, where he focused on the discovery of novel antibiotic agents. In 1990, he moved to Pfizer's computational chemistry group where he was responsible for developing Pfizer's in-house approach to virtual screening.

In 1998, Paul joined Prolifix, a UK biotechnology company which was acquired in 2002 by TopoTarget, a listed drug development company focused on oncology. Following this acquisition Paul became group director of R&D and was responsible for TopoTarget's extremely successful HDAC inhibitor programme (now in multiple Phase II trials).

Professor W. Graham Richards is one of the leading computational chemists in the UK, with over 300 publications.  He served as Chairman of the Department of Chemistry at Oxford University from 1997 to 2007. He is head of the Centre for Computational Drug Discovery at Oxford. Throughout his career, Professor Richards has been involved in the commercialisation of technologies. In 1989, he co-founded Oxford Molecular Ltd, which later floated on the London Stock Exchange as Oxford Molecular Group plc. In 2001, he founded InhibOx Ltd. He was a director of ISIS Innovation Ltd, the University of Oxford's technology transfer company and was involved for several years with the Wellcome Trust in a similar capacity. He is a main board director (formerly Chairman) of IP Group plc, the listed intellectual property commercialization company.

Barry has over twenty years of drug discovery experience working in the pharmaceutical industry. He was Chief Executive Officer of ReOx, a biotechnology spin out from the University of Oxford; a Non-Executive Director of Curidium; and recently, Director and Senior Vice President of Drug Discovery at De Novo Pharmaceuticals. Prior to that, Barry held senior positions at Pharmagene (Vice President, Therapeutics), Rhone-Poulenc Rorer (Senior Director of Medicinal Chemistry) and Glaxo Group Research (Research Leader). He gained his PhD from the University of California, San Diego followed by a post doctoral fellowship with Syntex in Palo Alto.

Andy was a founding member of the team at IP Group plc. Andy has extensive experience in the identification of valuable IP and establishing, building and financing spin-out companies around that IP. Andy holds a Ph.D. in physics.